BiVictriX Interim results for the six months ended 30 June 2022

September 12th, 2022

Alderley Park, 12 September 2022 – BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces its unaudited interim results for the six months ended 30 June 2022.

Please Read PDF RNS HERE